Lv11
30 积分 2024-10-17 加入
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
2小时前
待确认
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
2小时前
已完结
Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis
3个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
3个月前
已完结
Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer
3个月前
已完结
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
3个月前
已完结
Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register
3个月前
已关闭
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
3个月前
已完结
Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis
3个月前
已完结
皖公网安备34019202002308
